SCHEMBL12416583

SCHEMBL12416583

Cc1ccc2c(Br)ccc(F)c2n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 2/20 0.41
RAB9A P51151 1/20 0.41
CCR5 P51681 1/20 0.41
KMT2A Q03164 3/20 0.39
OPRK1 P41145 1/20 0.39
MAPT P10636 3/20 0.36
ADORA2A P29274 2/20 0.36
CTSB P07858 1/20 0.33
CTSH P09668 1/20 0.33
METAP2 P50579 1/20 0.32
EPRS1 P07814 1/20 0.32
KDM4E B2RXH2 2/20 0.32
USP2 O75604 2/20 0.32
NPC1 O15118 1/20 0.32
ALDH1A1 P00352 1/20 0.32
HPGD P15428 1/20 0.32
HSD17B10 Q99714 1/20 0.32
CCR8 P51685 1/20 0.31
ADORA1 P30542 1/20 0.31
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31556365 1.00 CCR1 (0.41) CCR1RAB9ACCR5KMT2AOPRK1
SCHEMBL737630 0.85 CCR1 (0.41) CCR1RAB9ACCR5KMT2AOPRK1
SCHEMBL17506427 0.80 KMT2A (0.50) CCR1RAB9ACCR5KMT2AOPRK1
SCHEMBL4703454 0.77 KMT2A (0.67) CCR1RAB9ACCR5KMT2AOPRK1
SCHEMBL3961491 0.77 CCR1 (0.41) CCR1RAB9ACCR5KMT2AOPRK1
SCHEMBL2171151 0.77 BACE1 (0.32) KMT2AMAPTALDH1A1MEN1
SCHEMBL874389 0.77 MAPT (0.47) CCR1RAB9ACCR5KMT2AOPRK1
SCHEMBL21957043 0.77 CCR1 (0.41) CCR1RAB9ACCR5KMT2AOPRK1
SCHEMBL2883600 0.77 KMT2A (0.56) CCR1RAB9ACCR5KMT2AOPRK1
SCHEMBL2172807 0.77 KMT2A (0.37) RAB9AKMT2AADORA2ANPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122152-A1 KAT6 Inhibitors BEIGENE SWITZERLAND GMBH (CH) 2025-04-17 US disclosed
US-8436015-B2 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use MERCK SHARP & DOHME CORP. (US) 2013-05-07 US disclosed
US-20110172256-A1 GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK SHARP & DOHME LLC 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172256-A1 GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE GCGR, GLP1R, GPR119 CCR1 1312/4885RAB9A 3427/4885CCR5 791/4885
US-20250122152-A1 KAT6 Inhibitors KAT6A, KAT6B, KAT7 CCR1 4688/4885RAB9A 3322/4885CCR5 4700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.